Cargando…
Clinical analysis of severe COVID-19 patients
BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028659/ https://www.ncbi.nlm.nih.gov/pubmed/35124599 http://dx.doi.org/10.3233/THC-228021 |
_version_ | 1784691676661415936 |
---|---|
author | Wang, Hao Sun, Bin Li, Xiayuan Wang, Yun Yang, Zhengping |
author_facet | Wang, Hao Sun, Bin Li, Xiayuan Wang, Yun Yang, Zhengping |
author_sort | Wang, Hao |
collection | PubMed |
description | BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospital were collected from January 31 to March 17. RESULTS: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group ([Formula: see text] 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group ([Formula: see text] 0.05). CONCLUSIONS: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19. |
format | Online Article Text |
id | pubmed-9028659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90286592022-05-06 Clinical analysis of severe COVID-19 patients Wang, Hao Sun, Bin Li, Xiayuan Wang, Yun Yang, Zhengping Technol Health Care Research Article BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospital were collected from January 31 to March 17. RESULTS: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group ([Formula: see text] 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group ([Formula: see text] 0.05). CONCLUSIONS: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19. IOS Press 2022-02-25 /pmc/articles/PMC9028659/ /pubmed/35124599 http://dx.doi.org/10.3233/THC-228021 Text en © 2022 – The authors. Published by IOS Press. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Hao Sun, Bin Li, Xiayuan Wang, Yun Yang, Zhengping Clinical analysis of severe COVID-19 patients |
title | Clinical analysis of severe COVID-19 patients |
title_full | Clinical analysis of severe COVID-19 patients |
title_fullStr | Clinical analysis of severe COVID-19 patients |
title_full_unstemmed | Clinical analysis of severe COVID-19 patients |
title_short | Clinical analysis of severe COVID-19 patients |
title_sort | clinical analysis of severe covid-19 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028659/ https://www.ncbi.nlm.nih.gov/pubmed/35124599 http://dx.doi.org/10.3233/THC-228021 |
work_keys_str_mv | AT wanghao clinicalanalysisofseverecovid19patients AT sunbin clinicalanalysisofseverecovid19patients AT lixiayuan clinicalanalysisofseverecovid19patients AT wangyun clinicalanalysisofseverecovid19patients AT yangzhengping clinicalanalysisofseverecovid19patients |